Posts by Noëlle Aubert

Life Sciences cluster   The Biopôle site continues its strong development with the construction of three new buildings. By 2024, more than 23,000 additional square meters of office and laboratory space completely dedicated to life sciences will be built. The buildings will be built according to Minergie®-P standards, with wood-frame façades and surrounded by greenery,…

Close collaboration between biopharmaceutical companies & Canton de Neuchâtel   The Canton of Neuchâtel will open up a new dual-mode training route to meet the needs of the Neuchâtel economic fabric. From the beginning of the school year 2021-2022, training as a chemical and pharmaceutical production technologist will be offered in the Canton of Neuchâtel. In this…

A new platform in the field of Artificial Intelligence in medicine   The University of Bern & the Inselspital, Bern University Hospital, founded a “Center for Artificial Intelligence in Medicine” (CAIM) that combines cutting-edge research, engineering and digitalisation. Using artificial intelligence it will develop new medical technologies to enable tailor-made and efficient patient care. Partners…

Newly founded: MCIDI   The University of Bern established a multidisciplinary center to study the origin and course of infectious diseases and their impact on health, society and economics. The new research center, founded on January 1st 2021, is to receive some 30 million Swiss Francs financial support from the Vinetum Foundation over a period…

Switzerland is the Mecca of the pharmaceutical industry   ZETA, the engineering specialist for the pharmaceutical and biotech industries, manages 12 subsidiaries in seven countries worldwide. The latest subsidiary has recently been opened in Visp, a center of the Swiss pharmaceutical industry, with the aim of working even more closely with the global players and medium-sized companies in…

Dexter surgical robot  Distalmotion, a Swiss-based medical device company establishing a new global standard of care ensuring every patient can access the benefits of robotic surgery, announced that it received European CE Mark for its surgical robot Dexter. Manufactured in Switzerland, Dexter combines the affordability of laparoscopy with the benefits of robotic surgery to bring…

Antiviral Alisporivir: a valuable additional therapy to SOC   Debiopharm, a Swiss biopharmaceutical company, announced the first patient dosed in an investigator-initiated, randomised phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The study will be conducted by the AP-HP to assess the efficacy and safety of the cyclophilin inhibitor in the treatment…

Call for entries 2021 marks the 4th year that the Swiss Medtech Award recognises outstanding achievements in the Swiss medical technology industry. The race for the coveted trophy and prize money of CHF 50,000 to award outstanding achievements in the Swiss medical technology industry has begun. The jury is looking for candidates from the fields of…

EPFL scientists have developed a synthetic molecule capable of killing the virus that causes influenza. They hope their discovery will lead to an effective drug treatment. Influenza is one of the most widespread viral diseases and constitutes a major public health problem. Scientists at EPFL’s Supramolecular Nano-Materials and Interfaces Laboratory (SuNMIL) within the School of…

Co-develop the ER-004 treatment   The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention.  They announced today that they have entered into a license and development collaboration agreement for the development and commercialisation of ER-004, a prenatal…